xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06015503</url>
    </required_header>
    <id_info>
      <org_study_id>PLB1004-II-01</org_study_id>
      <nct_id>NCT06015503</nct_id>
    </id_info>
    <brief_title>A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)</brief_title>
    <acronym>Kannon</acronym>
    <official_title>A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Avistone Biotechnology Co., Ltd.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Avistone Biotechnology Co., Ltd.</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the&#xD;
        Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic&#xD;
        Non-small Cell Lung Cancer(NSCLC).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until&#xD;
        treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end&#xD;
        of study visit(EOS), safety follow-up and survival follow-up).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">July 21, 2023</start_date>
    <completion_date type="Anticipated">September 9, 2026</completion_date>
    <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>objective Response Rate (ORR)</measure>
      <time_frame>3 years</time_frame>
      <description>To evaluate the Objective Response Rate（ORR）which is defined by IRC as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>objective Response Rate (ORR)</measure>
      <time_frame>3 years</time_frame>
      <description>To evaluate the Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Control Rate ( DCR)</measure>
      <time_frame>3 years</time_frame>
      <description>DCR is defined as the percentage of participants achieving complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Duration of Response (DOR)</measure>
      <time_frame>3 years</time_frame>
      <description>DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Progression-Free Survival (PFS)</measure>
      <time_frame>3 years</time_frame>
      <description>PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall Survival (OS)</measure>
      <time_frame>3 years</time_frame>
      <description>OS is defined as the time from the date of the first dose until the date of death due to any cause.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intracranial Overall Response Rate（ORR）</measure>
      <time_frame>3 years</time_frame>
      <description>To evaluate the intracranial Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with Intracranial disease confirmed best overall response of complete response or partial response per RECIST v 1.1.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intracranial Disease Control Rate (DCR)</measure>
      <time_frame>3 years</time_frame>
      <description>Intracranial DCR is defined as the percentage of participants achieving Intracranial disease complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intracranial Disease Control Rate (DOR)</measure>
      <time_frame>3 years</time_frame>
      <description>Intracranial DOR is defined as the time from the date of first documented response (CR or PR) until the date of Intracranial disease documented progression or death, whichever comes first.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intracranial Progression-Free Survival (PFS)</measure>
      <time_frame>3 years</time_frame>
      <description>Intracranial PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs)</measure>
      <time_frame>2 years</time_frame>
      <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug assessed by CTCAE v5.0.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Incidence of abnormalities in Clinical Laboratory Assessments.</measure>
      <time_frame>2 years</time_frame>
      <description>Number of participants with abnormalities in Clinical Laboratory tests（including serum chemistry and hematology） will be reported.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Incidence of abnormalities in Vital Signs.</measure>
      <time_frame>2 years</time_frame>
      <description>Number of participants with abnormalities in vital signs(including temperature ,pulse/heart rate，and blood pressure) will be reported.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area Under the Curve（AUC0-t）of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The AUC values are based on the plasma concentration-time profile (from time 0 to Time of the Last Quantifiable Concentration) of PLB1004. To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area Under the Curve（AUC0-∞）of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The AUC values are based on the plasma concentration-time profile (from time 0 to infinity) of PLB1004. To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Maximum plasma concentration (Cmax) of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The Cmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time to maximum plasma concentration (Tmax) of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The Tmax values are based on the plasma concentration-time profile of PLB 1004.To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Half-life time (t1/2) of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The t1/2 values are based on the terminal disposition Phase Half-life for PLB1004 and its Active Metabolites. To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Apparent clearance (CL/F) of PLB1004</measure>
      <time_frame>Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose</time_frame>
      <description>The CL/F values are based on the apparent clearance after extravascular administration for PLB1004. To characterize the pharmacokinetics of PLB1004.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">157</enrollment>
    <condition>Non-Small-Cell Lung Cancer</condition>
    <arm_group>
      <arm_group_label>PLB1004</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>PLB1004 given alone as monotherapy</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>PLB1004</intervention_name>
      <description>PLB1004 is a capsule in the form of 80mg and 40mg.</description>
      <arm_group_label>PLB1004</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Ability to understand and willingness to sign a written informed consent document.&#xD;
  &#xD;
            2. Aged at least 18 years old.&#xD;
  &#xD;
            3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage&#xD;
               IIIB~IV).&#xD;
  &#xD;
            4. According to the prior treatments having received for advanced disease (platinum&#xD;
               containing or/and immunotherapy containing systemic therapy, not more than three&#xD;
               lines), participants were randomized to two cohorts.&#xD;
  &#xD;
            5. Participants with EGFR ex20ins mutation.&#xD;
  &#xD;
            6. ECOG performance status 0 to 1.&#xD;
  &#xD;
            7. Life expectancy is not less than 12 weeks.&#xD;
  &#xD;
            8. At least one measurable lesion as defined by RECISTV1.1.&#xD;
  &#xD;
            9. Participants must have specific organ and bone marrow function.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Exclusion&#xD;
  &#xD;
                 1. Having the anticancer therapy prior to the first dose of PLB1004 as follows:&#xD;
  &#xD;
                      1. Any monoclonal antibodies targeting EGFR/HER2/VEGFR within 4 weeks.&#xD;
  &#xD;
                      2. Any cytotoxic drugs or other anticancer drugs from a previous treatment&#xD;
                         regimen within 14 days.&#xD;
  &#xD;
                      3. Any anticancer herbal medicine within 7 days&#xD;
  &#xD;
                      4. Major surgery within 4 weeks prior to starting PLB1004 or who have not&#xD;
                         recovered from side effects of such procedure except for the biopsy of&#xD;
                         Thoracoscopy and the clinical test of Mediastinoscopy could ≤ 7 days prior&#xD;
                         to starting PLB1004..&#xD;
  &#xD;
                      5. Radiotherapy to lung fields and whole-brain fields ≤4 weeks prior to&#xD;
                         starting PLB1004. For all other anatomic sites, radiotherapy ≤2 weeks prior&#xD;
                         to starting PLB1004 or patients who have not recovered from&#xD;
                         radiotherapy-related toxicities. Palliative radiotherapy for bone lesions is&#xD;
                         not included.&#xD;
  &#xD;
                      6. Any anti-EGFR TKI for the EGFR ex20ins mutation.&#xD;
  &#xD;
                      7. Any third-generation anti-EGFR TKI during the treatment having achieved a&#xD;
                         best overall response of the partial response or complete response.&#xD;
  &#xD;
                 2. Had not recovered from the adverse events and comorbidities caused by prior&#xD;
                    Systemic chemotherapy ,surgery ,radiotherapy to ≤ Grade 1（except for hair loss&#xD;
                    and permanent radiotherapy damage ）,the neurological toxicity caused by platinum&#xD;
                    could ≤ Grade 2.&#xD;
  &#xD;
                 3. Patients receiving treatment with medications that meet one of the following&#xD;
                    criteria and that cannot be discontinued at least 1 week prior to the start of&#xD;
                    treatment with PLB1004 and for the duration of the study:&#xD;
  &#xD;
                      -  Strong inhibitors of CYP3A4&#xD;
  &#xD;
                      -  Strong inducers of CYP3A4&#xD;
  &#xD;
                      -  metformin a MATE transporter substrate&#xD;
  &#xD;
                 4. Patients with spinal cord compression ,brain membrane metastasis and symptomatic&#xD;
                    central nervous system (CNS), who are neurologically unstable or have required&#xD;
                    increasing doses of steroids within the 2 weeks prior to study manage CNS&#xD;
                    symptoms.&#xD;
  &#xD;
                 5. Patients with uncontrolled and symptomatic pleural effusions, peritoneal&#xD;
                    effusions and pericardial effusions within 4 weeks prior to the start of&#xD;
                    treatment with PLB1004.&#xD;
  &#xD;
                 6. Presence or history of a malignant disease other than NSCLC that has been&#xD;
                    diagnosed and/or required therapy within the past 3 years. Exceptions to this&#xD;
                    exclusion include the following: completely resected basal cell and squamous cell&#xD;
                    skin cancers, indolent malignancies that currently do not require treatment, and&#xD;
                    completely resected carcinoma in situ of any type.&#xD;
  &#xD;
                 7. Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
                    disease, radiation pneumonitis which required steroid treatment, or any evidence&#xD;
                    of clinically active interstitial lung disease.&#xD;
  &#xD;
                 8. Konwn positive hepatitis B (hepatitis B virus , HBV) surface antigen(HBsAg) and&#xD;
                    HBV-DNA test value≥ULN.&#xD;
  &#xD;
                 9. known positive hepatitis C antibody(anti-HCV) and Anti-HIV(+).Note: Subjects with&#xD;
                    a prior history of HCV, who have completed antiviral treatment and have&#xD;
                    subsequently documented HCV RNA below the lower limit of quantification per local&#xD;
                    testing are eligible.&#xD;
  &#xD;
                10. Having significant or uncontrolled systemic disease, including but not limited&#xD;
                    to:&#xD;
  &#xD;
                      1. Poorly controlled hypertension (referring to systolic blood pressure&gt;100&#xD;
                         mmHg after treatment) .&#xD;
  &#xD;
                      2. Ongoing or active infection.&#xD;
  &#xD;
                      3. Keratitis or onset of ulcerative keratitis.&#xD;
  &#xD;
                      4. Other significant disease, mental illness or laboratory abnormalities that&#xD;
                         could affect the compliance of the patient on the protocol or investigator's&#xD;
                         judgement.&#xD;
  &#xD;
                11. Clinically significant, uncontrolled heart disease, including but not limited to:&#xD;
  &#xD;
                      1. Abnormal QT interval on screening electrocardiogram (ECG), defined as the&#xD;
                         average value of triplicate QTcF&gt;470ms.&#xD;
  &#xD;
                      2. Have significant arrhythmias such as ventricular arrhythmia,&#xD;
                         supraventricular arrhythmia which could not be controlled by drugs, nodal&#xD;
                         arrhythmia and other cardiac arrhythmias which could not be controlled by&#xD;
                         drugs, Grade≥3 of Congestive heart failure by the New York Heart Association&#xD;
                         (NYHA).&#xD;
  &#xD;
                      3. Any factors that increase the risk of QTc interval prolongation, such as&#xD;
                         hypokalemia, genetic long QT syndrome, taking drugs that causing the QT&#xD;
                         interval prolongation.&#xD;
  &#xD;
                12. Medical history of deep vein thrombosis or pulmonary embolism within 6 months&#xD;
                    prior to enrolment or any of the following: Myocardial infarction, unstable&#xD;
                    angina, stroke, transient ischemic attack, coronary/peripheral artery bypass&#xD;
                    graft, or any acute coronary syndrome. Or bleeding tendencies or hypercoagulable&#xD;
                    coagulopathy within 6 months prior to first dose.&#xD;
  &#xD;
                13. Have active digestive system disease, or major gastrointestinal surgery which may&#xD;
                    significantly affect the taking or absorption of PLB1004(such as ulcerative&#xD;
                    lesions, uncontrollable nausea, vomiting, diarrhea, and malabsorption syndrome).&#xD;
  &#xD;
                14. History of hypersensitivity to active or inactive excipients of PLB1004 or drugs&#xD;
                    with a similar chemical structure of class to PLB1004.&#xD;
  &#xD;
                15. pregnant or nursing women.&#xD;
  &#xD;
                16. Judgment by the investigator that the patient should not participate in the study&#xD;
                    if the patient is unlikely to comply with study procedures, restrictions and&#xD;
                    requirements.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Yilong Wu, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Guangdong Provincial People's Hospital</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Weizhe Xue</last_name>
      <phone>+86-010-84148931</phone>
      <email>xueweizhe@avistonebio.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Guangdong General Hospital</name>
        <address>
          <city>Guangzhou</city>
          <state>Guangdong</state>
          <zip>510080</zip>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Jinji Yang, MD</last_name>
        <phone>+86-20-83827812</phone>
        <phone_ext>50810</phone_ext>
        <email>yangjinji@gdph.org.cn</email>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 18, 2023</study_first_submitted>
    <study_first_submitted_qc>August 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 29, 2023</study_first_posted>
    <last_update_submitted>August 25, 2023</last_update_submitted>
    <last_update_submitted_qc>August 25, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 29, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Non-Small-Cell Lung Cancer</keyword>
    <keyword>EGFR</keyword>
    <keyword>NSCLC</keyword>
    <keyword>Lung Cancer</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lung Neoplasms</mesh_term>
      <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06015503
  org study id: PLB1004-II-01
  nct id: NCT06015503
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the
        Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic
        Non-small Cell Lung Cancer(NSCLC).
  This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until
        treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end
        of study visit(EOS), safety follow-up and survival follow-up).
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: objective Response Rate (ORR)
  time frame: 3 years
  description: To evaluate the Objective Response Rate（ORR）which is defined by IRC as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.
  measure: objective Response Rate (ORR)
  time frame: 3 years
  description: To evaluate the Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.
  measure: Disease Control Rate ( DCR)
  time frame: 3 years
  description: DCR is defined as the percentage of participants achieving complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1
  measure: Duration of Response (DOR)
  time frame: 3 years
  description: DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first.
  measure: Progression-Free Survival (PFS)
  time frame: 3 years
  description: PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.
  measure: Overall Survival (OS)
  time frame: 3 years
  description: OS is defined as the time from the date of the first dose until the date of death due to any cause.
  measure: Intracranial Overall Response Rate（ORR）
  time frame: 3 years
  description: To evaluate the intracranial Overall Response Rate（ORR）which is defined by investigator as the proportion of subjects with Intracranial disease confirmed best overall response of complete response or partial response per RECIST v 1.1.
  measure: Intracranial Disease Control Rate (DCR)
  time frame: 3 years
  description: Intracranial DCR is defined as the percentage of participants achieving Intracranial disease complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1.
  measure: Intracranial Disease Control Rate (DOR)
  time frame: 3 years
  description: Intracranial DOR is defined as the time from the date of first documented response (CR or PR) until the date of Intracranial disease documented progression or death, whichever comes first.
  measure: Intracranial Progression-Free Survival (PFS)
  time frame: 3 years
  description: Intracranial PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.
  measure: Incidence of Treatment-Emergent Adverse Events (TEAEs)
  time frame: 2 years
  description: A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug assessed by CTCAE v5.0.
  measure: Incidence of abnormalities in Clinical Laboratory Assessments.
  time frame: 2 years
  description: Number of participants with abnormalities in Clinical Laboratory tests（including serum chemistry and hematology） will be reported.
  measure: Incidence of abnormalities in Vital Signs.
  time frame: 2 years
  description: Number of participants with abnormalities in vital signs(including temperature ,pulse/heart rate，and blood pressure) will be reported.
  measure: Area Under the Curve（AUC0-t）of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The AUC values are based on the plasma concentration-time profile (from time 0 to Time of the Last Quantifiable Concentration) of PLB1004. To characterize the pharmacokinetics of PLB1004.
  measure: Area Under the Curve（AUC0-∞）of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The AUC values are based on the plasma concentration-time profile (from time 0 to infinity) of PLB1004. To characterize the pharmacokinetics of PLB1004.
  measure: Maximum plasma concentration (Cmax) of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The Cmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.
  measure: Time to maximum plasma concentration (Tmax) of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The Tmax values are based on the plasma concentration-time profile of PLB 1004.To characterize the pharmacokinetics of PLB1004.
  measure: Half-life time (t1/2) of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The t1/2 values are based on the terminal disposition Phase Half-life for PLB1004 and its Active Metabolites. To characterize the pharmacokinetics of PLB1004.
  measure: Apparent clearance (CL/F) of PLB1004
  time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose
  description: The CL/F values are based on the apparent clearance after extravascular administration for PLB1004. To characterize the pharmacokinetics of PLB1004.
  arm group label: PLB1004
  arm group type: Experimental
  description: PLB1004 given alone as monotherapy
  intervention type: Drug
  intervention name: PLB1004
  description: PLB1004 is a capsule in the form of 80mg and 40mg.
  arm group label: PLB1004
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Yilong Wu, MD
  role: Principal Investigator
  affiliation: Guangdong Provincial People's Hospital
  last name: Weizhe Xue
  phone: +86-010-84148931
  email: xueweizhe@avistonebio.com
  facility: 
  status: Recruiting
  contact: 
  country: China
  responsible party type: Sponsor
  mesh term: Lung Neoplasms
  mesh term: Carcinoma, Non-Small-Cell Lung
  sharing ipd: No